AGIO Stock Overview
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Agios Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$33.44 |
52 Week High | US$35.50 |
52 Week Low | US$19.80 |
Beta | 0.81 |
1 Month Change | 10.69% |
3 Month Change | 12.29% |
1 Year Change | 25.24% |
3 Year Change | -40.61% |
5 Year Change | -30.20% |
Change since IPO | 6.91% |
Recent News & Updates
Recent updates
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced
Sep 07Agios submits mitapivat application in U.S. for pyruvate kinase deficiency
Jun 21Shareholder Returns
AGIO | US Biotechs | US Market | |
---|---|---|---|
7D | -4.9% | 0.07% | -0.2% |
1Y | 25.2% | 6.9% | 28.2% |
Return vs Industry: AGIO exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: AGIO underperformed the US Market which returned 27.7% over the past year.
Price Volatility
AGIO volatility | |
---|---|
AGIO Average Weekly Movement | 5.9% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: AGIO has not had significant price volatility in the past 3 months.
Volatility Over Time: AGIO's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 385 | Brian Goff | www.agios.com |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Agios Pharmaceuticals, Inc. Fundamentals Summary
AGIO fundamental statistics | |
---|---|
Market cap | US$1.92b |
Earnings (TTM) | -US$352.62m |
Revenue (TTM) | US$29.40m |
64.6x
P/S Ratio-5.4x
P/E RatioIs AGIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AGIO income statement (TTM) | |
---|---|
Revenue | US$29.40m |
Cost of Revenue | US$299.80m |
Gross Profit | -US$270.40m |
Other Expenses | US$82.22m |
Earnings | -US$352.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -6.21 |
Gross Margin | -919.62% |
Net Profit Margin | -1,199.26% |
Debt/Equity Ratio | 0% |
How did AGIO perform over the long term?
See historical performance and comparison